TrovaGene Inc  

(Public, NASDAQ:TROV)   Watch this stock  
Find more results for trov
+0.015 (3.95%)
Mar 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.38 - 0.42
52 week 0.23 - 1.63
Open 0.38
Vol / Avg. 2.12M/2.82M
Mkt cap 22.70M
P/E     -
Div/yield     -
EPS -0.76
Shares 55.29M
Beta 0.06
Inst. own 10%
May 8, 2018
Q1 2018 Trovagene Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 22, 2018
Trovagene Inc at Wall Street Investor Forum - 9:35AM EDT - Add to calendar
Feb 26, 2018
Q4 2017 Trovagene Inc Earnings Release
Jan 9, 2018
Trovagene Inc at EBD Group Biotech Showcase
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin -1388.66% -4928.12%
Operating margin -2045.22% -5392.09%
EBITD margin - -4387.41%
Return on average assets -84.12% -88.58%
Return on average equity -197.69% -189.78%
Employees 17 -
CDP Score - -


11055 Flintkote Ave
SAN DIEGO, CA 92121-1220
United States - Map
+1-858-2175420 (Phone)
+1-858-2174768 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers. PCM-075 developed high selectivity to PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase Ib/II clinical trial in patients with AML underway.

Officers and directors

Thomas H. Adams Jr. Ph.D. Chairman of the Board
Age: 74
Bio & Compensation  - Reuters
William J. Welch Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Athena M. Countouriotis M.D. Director
Age: 45
Bio & Compensation  - Reuters
Paul R. Billings M.D. Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
John P. Brancaccio CPA Independent Director
Age: 69
Bio & Compensation  - Reuters
Gary S. Jacob Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Rodney S. Markin M.D., Ph.D. Independent Director
Age: 58
Bio & Compensation  - Reuters